Table 1:
Baseline patient characteristics (n=1,329) stratified by SVR status
| Characteristic | Total (n=1329) nb (%) | SVR (n = 1277) | Non-SVR (n=52) |
|---|---|---|---|
| Sociodemographic Features | |||
| Age | |||
| <35 | 59 (4) | 58 (4) | 1 (2) |
| 35-55 | 292 (22) | 279 (22) | 13 (25) |
| >55 | 978 (74) | 940 (74) | 38 (73) |
| Sex | |||
| Female | 602 (45) | 582 (46) | 20 (38) |
| Male | 727 (55) | 695 (54) | 32 (62) |
| Race | |||
| Black | 801 (60) | 423 (33) | 19 (36) |
| White | 442 (33) | 769 (60) | 32 (62) |
| Other | 81 (7) | 80 (7) | 1 (2) |
| Ethnicity | |||
| Not Hispanic or Latino | 1038 (83) | 993 (82) | 45 (88) |
| Hispanic or Latino | 55 (4) | 53 (4) | 2 (4) |
| Other | 170 (13) | 166 (14) | 4 (8) |
| Education | |||
| Up to High school diploma or GED | 707 (54) | 683 (54) | 24 (49) |
| Vocational school or higher | 607 (46) | 582 (46) | 25 (51) |
| Annual Income | |||
| Under $40,000 per year | 932 (72) | 901 (72) | 31 (65) |
| $41,000 or above per year | 361 (28) | 344 (28) | 17 (35) |
| Employment status | |||
| Working full or part time | 480 (38) | 460 (37) | 20 (41) |
| Unemployed | 75 (6) | 74 (6) | 1 (2) |
| Disabled/applying | 558 (43) | 536 (44) | 22 (45) |
| Retired/homemaker/student | 170 (13) | 164 (13) | 6 (12) |
| Clinical and Treatment Features | |||
| Genotype | |||
| 1, 4, 6 | 1087 (83) | 1044 (83) | 43 (82) |
| 2 | 118 (9) | 114 (9) | 4 (8) |
| 3 | 110 (8) | 105 (8) | 5 (10) |
| Cirrhosis Status | |||
| Cirrhosis Not present | 709 (53) | 687 (54) | 22 (42) |
| Cirrhosis present | 617 (47) | 587 (46) | 30 (58) |
| MELD | |||
| 6-11 | 448 (87) | 425 (87) | 23 (85) |
| 12 or above | 68 (13) | 64 (13) | 4 (15) |
| DAA Treatment Cohorta | |||
| SOF/LED | 836 (63) | 809 (63) | 27 (51) |
| SOF/VEL | 277 (21) | 262 (21) | 15 (29) |
| GRZ/ELB | 144 (11) | 138 (11) | 6 (12) |
| OBV/PTV/r + DSV | 55 (4) | 52 (4) | 3 (6) |
| SOF/DAC | 17 (1) | 16 (1) | 1 (2) |
| Treatment Duration | |||
| 8 weeks | 132 (10) | 127 (10) | 5 (10) |
| 12 weeks | 1091 (82) | 1049 (82) | 42 (80) |
| 16 or 24 weeks | 106 (8) | 101 (8) | 5 (10) |
| Treatment Experience | |||
| Treatment naive | 1073 (81) | 1038 (81) | 35 (67) |
| Treatment experienced | 255 (19) | 238 (19) | 17 (33) |
| Ribavirin | |||
| Without Ribavirin | 1155 (87) | 1113 (87) | 42 (81) |
| With Ribavirin | 174 (13) | 164 (13) | 10 (19) |
| Medical conditions | |||
| 0-1 | 263 (20) | 255 (20) | 8 (15) |
| 2-3 | 329 (25) | 311 (24) | 18 (35) |
| ≥4 | 735 (55) | 709 (56) | 26 (50) |
| Mental Health and Substance Use Features | |||
| Lifetime Mental Health Disturbance | |||
| No | 863 (65) | 828 (65) | 35 (67) |
| Yes | 460 (35) | 443 (35) | 17 (33) |
| Alcohol Misuse | |||
| No | 1132 (86) | 1087 (86) | 45 (87) |
| Yes | 190 (14) | 183 (14) | 7 (13) |
| Substance Use in the Past Year | |||
| No | 1033 (78) | 991 (78) | 42 (81) |
| Yes | 290 (22) | 280 (22) | 10 (19) |
NOTE:
a
DAA: Direct-Acting Antiviral, SOF/LED: sofosbuvir/ledipasvir, SOF/VEL: sofosbuvir/velpatasvir, GRZ/ELB: grazoprevir/elbasvir, OBV/PTV/r + DSV: ombitasvir/paritaprevir/ritonavir+dasabuvir, SOF/DAC: Sofosbuvir/Daclatasvir, SVR: Sustained Virologic Response.